At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
irinotecan +2 moredrug
Likely dose
irinotecan 60 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating irinotecan, Carboplatin, and 1 other intervention for Small Cell Lung Cancer. Completed, enrolled 37 participants across 10 sites.
Detailed Summary
This proposed Phase II trial will investigate the combination of irinotecan and carboplatin followed by sunitinib in the first-line treatment of patients with extensive-stage SCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2008
Primary CompletionJun 2011
Study CompletionSep 2012
TodayJul 2026
First PostedJun 11, 2008
Enrollment StartJun 1, 2008
Primary CompletionJun 1, 2011
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.1 years ago
Interventions
irinotecandrug
irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
Carboplatindrug
carboplatin AUC=4 on Day 1
sunitinibdrug
sunitinib 25 mg orally (PO) daily after initial chemotherapy